Literature DB >> 11034528

Hepatitis B prevalence in young women living in low-income areas: the population-based San Francisco Bay area's Young Women's Survey.

M T Hernandez1, J D Klausner, W McFarland, E Wong, G Bolan, F Molitor, J D Ruiz.   

Abstract

BACKGROUND: The risk of sexually transmitted hepatitis B virus infection is proportionally higher for young adults and women. Low socioeconomic groups have high rates of hepatitis B infection with no identified source of transmission. The prevalence and correlates of transmission of hepatitis B virus among young women of low socioeconomic status have not been well documented. GOAL: To determine the population-based prevalence and correlates of sexually acquired hepatitis B virus infection in young low-income women in the San Francisco Bay Area. STUDY
DESIGN: A three-county, door-to-door serosurvey of hepatitis B virus core antibody among young women living in low-income areas was conducted from April 1996 to January 1998. Multivariate analysis of sexually acquired hepatitis B virus infection excluded participants of Asian or Pacific Islander ethnicity or with a history of intravenous drug use or transfusion.
RESULTS: The prevalence of sexually acquired hepatitis B virus infection was 6.4% (95% CI, 4.7%-8.1%). Correlates of infection were black race (odds ratio, 3.9; 95% CI, 1.2-11.9 compared with white race) and herpes simplex virus type 2 infection (odds ratio, 2.0; 95% CI, 1.0-3.9).
CONCLUSIONS: Young black women have a higher risk of sexually acquired hepatitis B virus infection. Herpes simplex virus type 2 infection may predispose to hepatitis B virus infection and/or be a marker for lifetime sexual risk behavior.

Entities:  

Mesh:

Year:  2000        PMID: 11034528     DOI: 10.1097/00007435-200010000-00007

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  6 in total

1.  Hepatitis C virus infection in young, low-income women: the role of sexually transmitted infection as a potential cofactor for HCV infection.

Authors:  Kimberly A Page-Shafer; Barbara Cahoon-Young; Jeffrey D Klausner; Scott Morrow; Fred Molitor; Juan Ruiz; Willi McFarland
Journal:  Am J Public Health       Date:  2002-04       Impact factor: 9.308

Review 2.  Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users.

Authors:  Antonio L Estrada
Journal:  Public Health Rep       Date:  2002       Impact factor: 2.792

3.  Association between syphilis, antibodies to herpes simplex virus type 2, and recreational drug use and hepatitis B virus infection in the Women's Interagency HIV Study.

Authors:  Phyllis C Tien; Andrea Kovacs; Peter Bacchetti; Audrey L French; Michael Augenbraun; Stephen R Cole; Nancy Hessol; Jessica Justman
Journal:  Clin Infect Dis       Date:  2004-10-07       Impact factor: 9.079

4.  A community-based study of hepatitis B infection and immunization among young adults in a high-drug-use neighborhood in New York City.

Authors:  Benny J Kottiri; Samuel R Friedman; Gary L Euler; Peter L Flom; Milagros Sandoval; Alan Neaigus; Don C Des Jarlais; Jonathan M Zenilman
Journal:  J Urban Health       Date:  2005-07-20       Impact factor: 3.671

5.  The Seroprevalence of Hepatitis B in Akbar Abad Village, Kavar, Southern Iran.

Authors:  Mohammad Reza Fattahi; Davood Mehrabani; Sara Mehvarz; Najmeh Zarei Jaliani; Abbas Alipour; Mohammad Ali Davarpanah
Journal:  Int J Prev Med       Date:  2014-12

6.  National Survey of Morbidity and Risk Factors (EMENO): Protocol for a Health Examination Survey Representative of the Adult Greek Population.

Authors:  Giota Touloumi; Anna Karakatsani; Argiro Karakosta; Eleni Sofianopoulou; Panagiotis Koustenis; Magda Gavana; Yannis Alamanos; Maria Kantzanou; George Konstantakopoulos; Xenia Chryssochoou; Alexis Benos; Apostolos Vantarakis; Christos Hadjichristodoulou; Gregory Chlouverakis; Gregory Trypsianis; Paraskevi V Voulgari; Konstantinos Makrilakis; Stavros Liatis; George Stergiou
Journal:  JMIR Res Protoc       Date:  2019-02-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.